A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 14 Dec 2015 Results of retrospective analysis of COMPARZ study as well as pooled data from phase II (VEG102616) and phase III (VEG105192) studies of pazopanib have been published in the European Journal of Cancer
- 02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jan 2011 Planned end date changed from 1 Jun 2007 to 1 Oct 2012 as reported by ClinicalTrials.gov.